- Testimonials
- Injection Techniques

A A A Text Size

Email a Friend

Print this Page

Clinical Efficacy

Raising the standard—only Euflexxa^® delivers SATISFUNCTION™

Bioengineered for similarity to healthy human HA³

In patients with OA knee pain:

Significantly more patients pain free (P=0.038)¹
Significantly more patients with symptom-free function (P=0.003)¹
Rapid onset of pain relief evident by the third week of treatment²

References: 1. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14:154-162. 2. Data on file. Ferring Pharmaceuticals Inc. 3. Data on file. Bio-Technology General (Israel) Ltd.

spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer spacer

EUFLEXXA (1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).

Important Safety Information
EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA. The safety and effectiveness of repeated treatment cycles weeks with EUFLEXXA have not been established.

In a randomized, double-blind, multicenter clinical trial (N=160 EUFLEXXA), the only adverse event reported with EUFLEXXA at an incidence greater than 5% was arthralgia (8.7%).

Full Prescribing Information.

Important Information for Patients.

The information on this website is provided for educational purposes only. While there may be information on this web site related to certain medical conditions and their treatment, should a medical condition exist, promptly see your own physician or health provider as the information on this website is not intended to take the place of advice from a physician or healthcare professional. Ferring does not offer personalised medical diagnosis or patient-specific treatment advice. The statements made by doctors on this website represent their own individual experience and opinion and is not intended to be medical advice. Indeed, only your doctor or other health care professional, as a learned intermediary, can determine if a product described in this web site is appropriate for you.

PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.

This website is intended only for US residents.